News on lab-developed tests and emerging diagnostic technologies.
The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.
As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
